Home » Stocks » uniQure

uniQure N.V. (QURE)

Stock Price: $39.10 USD 1.56 (4.16%)
Updated Oct 20, 2020 2:22 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 1.74B
Revenue (ttm) 5.31M
Net Income (ttm) -135.58M
Shares Out 44.45M
EPS (ttm) -3.13
PE Ratio n/a
Forward PE 26.46
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 20, 2020
Last Price $39.10
Previous Close $37.54
Change ($) 1.56
Change (%) 4.16%
Day's Open 37.67
Day's Range 37.60 - 39.24
Day's Volume 337,357
52-Week Range 34.38 - 76.69

More Stats

Market Cap 1.74B
Enterprise Value 1.49B
Earnings Date (est) Nov 3, 2020
Ex-Dividend Date n/a
Shares Outstanding 44.45M
Float 35.22M
EPS (basic) -3.14
EPS (diluted) -3.13
FCF / Share -2.65
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.00M
Short Ratio 8.99
Short % of Float 11.36%
Beta 1.12
PE Ratio n/a
Forward PE 26.46
P/FCF Ratio n/a
PS Ratio 327.28
PB Ratio 6.16
Revenue 5.31M
Operating Income -139.51M
Net Income -135.58M
Free Cash Flow -117.58M
Net Cash 243.12M
Net Cash / Share 5.47
Gross Margin -1,647.01%
Operating Margin -2,627.33%
Profit Margin -2,553.30%
FCF Margin -2,214.35%
ROA -26.82%
ROE -68.21%
ROIC -123.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (16)

Buy 11
Overweight 2
Hold 3
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$72.50*
(85.42% upside)
Low
52.0
Current: $39.10
High
91.0
Target: 72.50
*Average 12-month price target from 14 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue7.2811.2813.1125.1010.586.14
Revenue Growth-35.48%-13.91%-47.78%137.27%72.25%-
Gross Profit7.2811.2813.1125.1010.586.14
Operating Income-123-90.38-86.77-73.41-71.93-54.70
Net Income-124-83.30-79.26-73.37-82.08-49.78
Shares Outstanding40.0035.6426.9825.0422.0817.12
Earnings Per Share-3.11-2.34-2.94-2.93-3.72-2.91
Operating Cash Flow-98.68-76.04-64.27-72.197.47-36.85
Capital Expenditures-5.65-2.38-4.46-15.29-7.61-22.20
Free Cash Flow-104-78.42-68.73-87.48-0.14-59.05
Cash & Equivalents378235159132222-
Total Debt73.0635.4720.7920.2420.21-
Net Cash / Debt305199139112201-
Assets449274210190263-
Liabilities12694.30120127135-
Book Value32318089.3663.63128-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name uniQure N.V.
Country Netherlands
Employees 248
CEO Matthew C. Kapusta

Stock Information

Ticker Symbol QURE
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: QURE
IPO Date June 20, 2007

Description

uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment of hemophilia A; and AMT-190, an IV-administered adeno-associated virus 5-based gene therapy for the treatment of Fabry disease. In addition, it engages in developing AMT-150, a gene therapy candidate for the treatment of Spinocerebellar Ataxia Type 3 disease. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.